HEADER IMMUNE SYSTEM 04-MAY-12 2LSQ TITLE ANALOG OF THE FRAGMENT 197-221 OF BETA-1 ADRENORECEPTOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANALOG OF THE FRAGMENT 197-221 OF BETA-1 ADRENORECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: EXTRACELLULAR TOPOLOGICAL DOMAIN; COMPND 5 SYNONYM: BETA-1 ADRENORECEPTOR, BETA-1 ADRENOCEPTOR; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 4 ORGANISM_COMMON: HUMAN; SOURCE 5 ORGANISM_TAXID: 9606; SOURCE 6 OTHER_DETAILS: THE PEPTIDE WAS PREPARED BY AUTOMATIC SOLID PHASE SOURCE 7 SYNTHESIS (SPPS) USING THE FMOC STRATEGY STARTING FROM 0.25 MMOL OF SOURCE 8 COMMERCIAL N FMOC-LYS(BOC)-POLYMER (BACHEM, SWITZERLAND). A SOURCE 9 COPOLYMER OF STYRENE WITH 1% DIVINYLBENZENE WITH A SOURCE 10 HYDROXYMETHYLPHENYLOXYMETHYL ANCHORING GROUP (THE WANG-POLYMER) WAS SOURCE 11 USED AS A CARRIER. THE SIDE FUNCTIONS OF THE AMINO ACIDS WERE SOURCE 12 BLOCKED BY THE FOLLOWING PROTECTIVE GROUPS: BUT FOR HYDROXYL SOURCE 13 FUNCTIONS OF SER AND TYR; BUT FOR CARBOXYL FUNCTIONS OF ASP AND GLU; SOURCE 14 BOC FOR -AMINO FUNCTIONS OF LYS; TRT FOR CARBOXYLAMIDE GROUP OF ASN, SOURCE 15 SULFHYDRYL FUNCTIONS OF RESIDUES CYS198 AND CYS220; ACM FOR SOURCE 16 SULFHYDRYL FUNCTIONS OF RESIDUES CYS209 AND CYS215, AND PBF FOR SOURCE 17 GUANIDINE FUNCTION OF ARG. THE AMINO ACID CHAIN WAS ELONGATED SOURCE 18 STEPWISE STARTING FROM C-TERMINUS USING CARBODIIMIDE IN THE PRESENCE SOURCE 19 OF 1-HYDROXYBENZOTRIASOLE. WHEN THE SPPS WAS FINISHED, THE PEPTIDE SOURCE 20 WAS CLEAVED FROM CARRIER WITH THE SIMULTANEOUS REMOVAL OF THE ACID- SOURCE 21 LABILE PROTECTIVE GROUPS BY TREATMENT WITH TRIFLUORACETIC ACID WITH SOURCE 22 THE ADDITION OF WATER, TRIISOPROPYLSILANE AND DITHIOTHREITOLE. THE SOURCE 23 SYNTHESIZED [CYS(ACM)2]PEPTIDE WAS PURIFIED BY HPLC TO A PURITY 85- SOURCE 24 90%. THE INTRAMOLECULAR S-S BRIDGE BETWEEN CYS198 AND CYS220 WAS SOURCE 25 WITH HYDROGEN PEROXIDE AT PH 8. THE TARGET MONOCYCLIC INTERMEDIATE SOURCE 26 OF PEPTIDE WAS PURIFIED BY HPLC TO A PURITY 90-95%. THE PRODUCT WAS SOURCE 27 CHARACTERIZED BY MALDI-TOF MASS SPECTROMETRY. THE SECOND DISULFIDE SOURCE 28 BOND BETWEEN CYS209 AND CYS215 WAS FORMED BY THE TREATMENT OF SOURCE 29 MONOCYCLIC INTERMEDIATE [CYS(ACM)2]PEPTIDE WITH IODINE (FOR SOURCE 30 SIMULTANEOUS CLEAVAGE OF ACM GROUP AND FORMATION S-S BRIDGE) IN SOURCE 31 METHANOL. THE BICYCLIC TARGET PRODUCT WAS PURIFIED BY HPLC TO A SOURCE 32 PURITY 98% AND CHARACTERIZED BY MALDI-TOF MASS SPECTROMETRY. KEYWDS BETA1-ADRENORECEPTOR, MODIFIED EXTRACELLULAR LOOP 197-221, KEYWDS 2 AUTOANTIBODIES, CARDIOMYOPATHY, ARRHYTHMIA, IMMUNE SYSTEM EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR V.N.BUSHUEV,K.A.ZYKOV,Z.D.BESPALOVA,R.S.BIBILASHVILI,E.E.EFREMOV, AUTHOR 2 S.P.GOLITSYN,L.I.KAZNACHEEVA,T.V.KUZHETSOVA,P.S.LEVASHOV, AUTHOR 3 V.P.MASENKO,N.A.MIRONOVA,F.S.MOLOKOEDOV,P.N.RUTKEVICH,A.V.RVACHEVA, AUTHOR 4 T.V.SHARF,M.V.SIDOROVA,T.N.VLASIK,E.V.YANUSHEVSKAYA REVDAT 2 14-JUN-23 2LSQ 1 REMARK REVDAT 1 08-MAY-13 2LSQ 0 JRNL AUTH V.N.BUSHUEV JRNL TITL ANALOG OF THE FRAGMENT 197-221 OF 1-ADRENORECEPTOR JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : XWINNMR 1.3, CYANA REMARK 3 AUTHORS : BRUKER BIOSPIN (XWINNMR), GUNTERT, MUMENTHALER AND REMARK 3 WUTHRICH (CYANA) REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2LSQ COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 07-MAY-12. REMARK 100 THE DEPOSITION ID IS D_1000102786. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 303 REMARK 210 PH : 5.5 REMARK 210 IONIC STRENGTH : 22 REMARK 210 PRESSURE : AMBIENT REMARK 210 SAMPLE CONTENTS : 2 MM PROTEIN, 1 MM SODIUM AZIDE, REMARK 210 20 MM [U-100% 2H] SODIUM ACETATE, REMARK 210 90% H2O/10% D2O; 2 MM PROTEIN, REMARK 210 1 MM SODIUM AZIDE, 20 MM [U-100% REMARK 210 2H] SODIUM ACETATE, 100% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-13C HSQC ALIPHATIC; 2D 1H REMARK 210 -13C HSQC AROMATIC; 2D DQF-COSY; REMARK 210 2D 1H-1H NOESY; 2D 1H-1H TOCSY REMARK 210 SPECTROMETER FIELD STRENGTH : 500 MHZ REMARK 210 SPECTROMETER MODEL : DPX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : XWINNMR 1.3, CARA 1.9.5, CYANA REMARK 210 3.0 REMARK 210 METHOD USED : TORSION ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : TARGET FUNCTION REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 TRP A 3 -165.52 -74.27 REMARK 500 1 ALA A 5 35.66 -87.29 REMARK 500 1 GLU A 6 13.36 -141.97 REMARK 500 1 CYS A 19 47.29 -153.77 REMARK 500 1 ASP A 21 -164.52 -61.46 REMARK 500 2 TRP A 3 -165.53 -74.67 REMARK 500 2 GLU A 6 15.44 -146.27 REMARK 500 2 ASN A 15 38.30 -95.94 REMARK 500 2 CYS A 19 46.90 -152.85 REMARK 500 2 ASP A 21 -164.13 -61.28 REMARK 500 3 TRP A 3 -167.75 -74.53 REMARK 500 3 GLU A 6 14.76 -142.12 REMARK 500 3 CYS A 19 47.34 -153.89 REMARK 500 3 ASP A 21 -164.18 -61.62 REMARK 500 3 CYS A 24 -174.81 -63.86 REMARK 500 4 TRP A 3 -167.52 -74.77 REMARK 500 4 GLU A 6 14.98 -144.28 REMARK 500 4 ASN A 15 35.16 -98.88 REMARK 500 4 CYS A 19 47.07 -153.48 REMARK 500 4 ASP A 21 -164.15 -61.69 REMARK 500 4 CYS A 24 -175.10 -63.82 REMARK 500 5 TRP A 3 -165.46 -74.25 REMARK 500 5 ALA A 5 35.43 -87.66 REMARK 500 5 GLU A 6 12.74 -141.80 REMARK 500 5 ASN A 15 38.36 -98.73 REMARK 500 5 CYS A 19 46.98 -153.07 REMARK 500 5 ASP A 21 -163.71 -61.23 REMARK 500 6 TRP A 3 -165.65 -74.80 REMARK 500 6 ALA A 5 31.71 -88.38 REMARK 500 6 GLU A 6 14.39 -141.69 REMARK 500 6 ASN A 15 35.66 -98.78 REMARK 500 6 CYS A 19 47.22 -153.72 REMARK 500 6 ASP A 21 -164.49 -61.46 REMARK 500 7 ALA A 5 39.11 -85.92 REMARK 500 7 GLU A 6 12.93 -142.05 REMARK 500 7 ASN A 15 38.00 -96.60 REMARK 500 7 CYS A 19 46.90 -152.73 REMARK 500 7 ASP A 21 -164.02 -61.60 REMARK 500 8 TRP A 3 -165.53 -74.67 REMARK 500 8 ALA A 5 36.71 -87.88 REMARK 500 8 GLU A 6 13.76 -143.71 REMARK 500 8 CYS A 19 47.41 -154.08 REMARK 500 8 ASP A 21 -164.07 -61.61 REMARK 500 9 ALA A 5 41.14 -86.03 REMARK 500 9 GLU A 6 13.51 -143.98 REMARK 500 9 CYS A 19 46.91 -153.08 REMARK 500 9 ASP A 21 -164.18 -61.47 REMARK 500 10 TRP A 3 -168.26 -74.55 REMARK 500 10 GLU A 6 15.89 -143.85 REMARK 500 10 ASN A 15 36.87 -98.66 REMARK 500 REMARK 500 THIS ENTRY HAS 100 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 18440 RELATED DB: BMRB REMARK 999 REMARK 999 SEQUENCE REMARK 999 AUTHORS STATE THAT THIS IS AN ANALOG OF THE FRAGMENT 197-221 OF REMARK 999 BETA-1 ADRENORECEPTOR. DBREF 2LSQ A 1 25 UNP P08588 ADRB1_HUMAN 197 221 SEQADV 2LSQ ASN A 1 UNP P08588 HIS 197 SEE REMARK 999 SEQADV 2LSQ CYS A 2 UNP P08588 TRP 198 SEE REMARK 999 SEQADV 2LSQ SER A 20 UNP P08588 CYS 216 SEE REMARK 999 SEQADV 2LSQ SER A 22 UNP P08588 PHE 218 SEE REMARK 999 SEQADV 2LSQ CYS A 24 UNP P08588 THR 220 SEE REMARK 999 SEQADV 2LSQ LYS A 25 UNP P08588 ASN 221 SEE REMARK 999 SEQRES 1 A 25 ASN CYS TRP ARG ALA GLU SER ASP GLU ALA ARG ARG CYS SEQRES 2 A 25 TYR ASN ASP PRO LYS CYS SER ASP SER VAL CYS LYS HELIX 1 1 ASP A 8 CYS A 13 1 6 HELIX 2 2 TYR A 14 SER A 20 5 7 SSBOND 1 CYS A 2 CYS A 24 1555 1555 2.11 SSBOND 2 CYS A 13 CYS A 19 1555 1555 2.11 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1